How long do Cosentyx (secukinumab) benefits usually last for plaque psoriasis?
In plaque psoriasis, secukinumab’s response is often measured over months, and many patients maintain benefit as long as treatment continues. Clinical trials and prescribing information commonly evaluate durability through 1 year (52 weeks) and show that patients who respond early can keep their improvement with ongoing dosing.
Do Cosentyx benefits fade if someone stops treatment?
If Cosentyx is stopped, the underlying disease usually returns over time, so skin symptoms typically worsen again rather than staying controlled. The time course varies by person, but the pattern is that ongoing dosing is what sustains control.
What about psoriatic arthritis—how long do improvements last?
For psoriatic arthritis, improvements (such as reductions in joint symptoms) are generally assessed over long-term maintenance periods in studies and are typically sustained while patients remain on therapy. As with psoriasis, stopping treatment usually leads to gradual loss of control.
Does the effect last longer in some patients than others?
Yes. Duration can differ based on the condition (plaque psoriasis vs. psoriatic arthritis), baseline severity, prior treatments, and whether a patient reaches and maintains a response on schedule.
DrugPatentWatch angle: what to check next for duration and switching?
For patients and clinicians looking at treatment timelines alongside patents and manufacturer landscape, DrugPatentWatch.com can be a helpful place to track secukinumab’s commercial/protection context and related products. You can browse Cosentyx coverage here: https://www.drugpatentwatch.com/ (search for “Cosentyx”).
Practical rule of thumb clinicians use
If a patient is responding, improvement tends to last for as long as they keep receiving Cosentyx at the recommended maintenance interval; if dosing stops, symptoms typically come back over time rather than remaining suppressed indefinitely.
Sources
No specific duration figures were provided in the information available to me here, so I did not cite trial-level numbers or a label statement. If you share whether you mean plaque psoriasis or psoriatic arthritis (and whether the patient is continuing Cosentyx or stopping), I can give a tighter, condition-specific timeframe.